Medicare AdvantageCoverageMedium impact
MA08.184, Cosibelimab-ipdl (Unloxcyt™)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jul 28, 2025
We identified it
Jun 19, 2026
Summary
A new Medicare Advantage policy MA08.184 has been established for Cosibelimab-ipdl (Unloxcyt™), a pharmacy drug. This is a brand new policy creating coverage guidelines for this medication under Medicare Advantage plans.
Action Required
By July 28, 2025: Billing team should review the full policy details at the provided URL to understand coverage criteria, prior authorization requirements, and billing procedures for Cosibelimab-ipdl (Unloxcyt™). Update pharmacy billing protocols and inform providers about any coverage restrictions or documentation requirements for this new drug.